Tsh Biopharmoration (Taiwan) Performance
| 8432 Stock | TWD 57.70 0.30 0.52% |
The entity has a beta of -0.0053, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Tsh Biopharmoration are expected to decrease at a much lower rate. During the bear market, Tsh Biopharmoration is likely to outperform the market. At this point, tsh biopharmoration has a negative expected return of -0.1%. Please make sure to validate Tsh Biopharmoration's mean deviation, standard deviation, total risk alpha, as well as the relationship between the coefficient of variation and jensen alpha , to decide if tsh biopharmoration performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days tsh biopharmoration has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest abnormal performance, the Stock's basic indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors. ...more
| Begin Period Cash Flow | 396.7 M | |
| Total Cashflows From Investing Activities | -10.1 M |
Tsh |
Tsh Biopharmoration Relative Risk vs. Return Landscape
If you would invest 6,130 in tsh biopharmoration on December 21, 2024 and sell it today you would lose (360.00) from holding tsh biopharmoration or give up 5.87% of portfolio value over 90 days. tsh biopharmoration is generating negative expected returns and assumes 1.0837% volatility on return distribution over the 90 days horizon. Simply put, 9% of stocks are less volatile than Tsh, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Tsh Biopharmoration Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tsh Biopharmoration's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as tsh biopharmoration, and traders can use it to determine the average amount a Tsh Biopharmoration's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0961
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 8432 |
Estimated Market Risk
| 1.08 actual daily | 9 91% of assets are more volatile |
Expected Return
| -0.1 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.1 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Tsh Biopharmoration is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Tsh Biopharmoration by adding Tsh Biopharmoration to a well-diversified portfolio.
Tsh Biopharmoration Fundamentals Growth
Tsh Stock prices reflect investors' perceptions of the future prospects and financial health of Tsh Biopharmoration, and Tsh Biopharmoration fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Tsh Stock performance.
| Return On Equity | 0.0635 | |||
| Return On Asset | 0.0387 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.16 % | |||
| Current Valuation | 1.17 B | |||
| Shares Outstanding | 38.4 M | |||
| Price To Earning | 56.63 X | |||
| Price To Book | 1.77 X | |||
| Price To Sales | 4.22 X | |||
| Revenue | 413.48 M | |||
| EBITDA | 71.41 M | |||
| Cash And Equivalents | 708.28 M | |||
| Cash Per Share | 18.36 X | |||
| Total Debt | 7.01 M | |||
| Debt To Equity | 0.60 % | |||
| Book Value Per Share | 27.67 X | |||
| Cash Flow From Operations | 68.71 M | |||
| Earnings Per Share | 1.78 X | |||
| Total Asset | 1.17 B | |||
About Tsh Biopharmoration Performance
Evaluating Tsh Biopharmoration's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Tsh Biopharmoration has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Tsh Biopharmoration has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
TSH Biopharm Corporation Limited develops, manufactures, and markets drugs for various chronic diseases in Taiwan and China. TSH Biopharm Corporation Limited is a subsidiary of TTY Biopharm Company Limited. TSH BIOPHARM is traded on Taiwan OTC Exchange in Taiwan.Things to note about tsh biopharmoration performance evaluation
Checking the ongoing alerts about Tsh Biopharmoration for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for tsh biopharmoration help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| tsh biopharmoration generated a negative expected return over the last 90 days | |
| About 65.0% of the company shares are owned by insiders or employees |
- Analyzing Tsh Biopharmoration's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Tsh Biopharmoration's stock is overvalued or undervalued compared to its peers.
- Examining Tsh Biopharmoration's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Tsh Biopharmoration's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Tsh Biopharmoration's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Tsh Biopharmoration's stock. These opinions can provide insight into Tsh Biopharmoration's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Tsh Stock Analysis
When running Tsh Biopharmoration's price analysis, check to measure Tsh Biopharmoration's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tsh Biopharmoration is operating at the current time. Most of Tsh Biopharmoration's value examination focuses on studying past and present price action to predict the probability of Tsh Biopharmoration's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tsh Biopharmoration's price. Additionally, you may evaluate how the addition of Tsh Biopharmoration to your portfolios can decrease your overall portfolio volatility.